دورية أكاديمية
أعرض في EDS

Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis.

التفاصيل البيبلوغرافية
العنوان: Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis.
المؤلفون: Bischof A; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA.; Department of Neurology with Institute for Translational Neurology, University Hospital Münster, Albert-Schweitzer-Campus 1, Münster, Germany., Papinutto N; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA., Keshavan A; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA., Rajesh A; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA., Kirkish G; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA., Zhang X; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA., Mallott JM; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA., Asteggiano C; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA., Sacco S; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA., Gundel TJ; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA., Zhao C; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA., Stern WA; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA., Caverzasi E; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA., Zhou Y; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA., Gomez R; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA., Ragan NR; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA., Santaniello A; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA., Zhu AH; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA., Juwono J; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA., Bevan CJ; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA., Bove RM; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA., Crabtree E; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA., Gelfand JM; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA., Goodin DS; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA., Graves JS; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA., Green AJ; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA., Oksenberg JR; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA., Waubant E; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA., Wilson MR; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA., Zamvil SS; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA., Cree BAC; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA., Hauser SL; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA., Henry RG; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA.
مؤلفون مشاركون: University of California, San Francisco MS-EPIC Team; Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA.
المصدر: Annals of neurology [Ann Neurol] 2022 Feb; Vol. 91 (2), pp. 268-281. Date of Electronic Publication: 2022 Jan 04.
نوع المنشور: Journal Article; Observational Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7707449 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1531-8249 (Electronic) Linking ISSN: 03645134 NLM ISO Abbreviation: Ann Neurol Subsets: MEDLINE
أسماء مطبوعة: Publication: New York, NY : Wiley-Liss
Original Publication: Boston, Little, Brown.
مواضيع طبية MeSH: Multiple Sclerosis, Relapsing-Remitting/*diagnostic imaging , Multiple Sclerosis, Relapsing-Remitting/*pathology , Spinal Cord/*pathology, Adult ; Atrophy ; Brain/diagnostic imaging ; Brain/pathology ; Disease Progression ; Female ; Foramen Magnum/diagnostic imaging ; Foramen Magnum/pathology ; Humans ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Predictive Value of Tests ; Prognosis ; Prospective Studies ; Spinal Cord/diagnostic imaging
مستخلص: Objective: A major challenge in multiple sclerosis (MS) research is the understanding of silent progression and Progressive MS. Using a novel method to accurately capture upper cervical cord area from legacy brain MRI scans we aimed to study the role of spinal cord and brain atrophy for silent progression and conversion to secondary progressive disease (SPMS).
Methods: From a single-center observational study, all RRMS (n = 360) and SPMS (n = 47) patients and 80 matched controls were evaluated. RRMS patient subsets who converted to SPMS (n = 54) or silently progressed (n = 159), respectively, during the 12-year observation period were compared to clinically matched RRMS patients remaining RRMS (n = 54) or stable (n = 147), respectively. From brain MRI, we assessed the value of brain and spinal cord measures to predict silent progression and SPMS conversion.
Results: Patients who developed SPMS showed faster cord atrophy rates (-2.19%/yr) at least 4 years before conversion compared to their RRMS matches (-0.88%/yr, p < 0.001). Spinal cord atrophy rates decelerated after conversion (-1.63%/yr, p = 0.010) towards those of SPMS patients from study entry (-1.04%). Each 1% faster spinal cord atrophy rate was associated with 69% (p < 0.0001) and 53% (p < 0.0001) shorter time to silent progression and SPMS conversion, respectively.
Interpretation: Silent progression and conversion to secondary progressive disease are predominantly related to cervical cord atrophy. This atrophy is often present from the earliest disease stages and predicts the speed of silent progression and conversion to Progressive MS. Diagnosis of SPMS is rather a late recognition of this neurodegenerative process than a distinct disease phase. ANN NEUROL 2022;91:268-281.
(© 2021 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.)
التعليقات: Comment in: Ann Neurol. 2022 May;91(5):735-736. (PMID: 35233827)
Comment in: Ann Neurol. 2022 May;91(5):734-735. (PMID: 35253269)
References: Sci Rep. 2016 Oct 27;6:36151. (PMID: 27786306)
J Neuroimaging. 2018 Nov;28(6):556-586. (PMID: 30102003)
J Chiropr Med. 2016 Jun;15(2):155-63. (PMID: 27330520)
Mult Scler Relat Disord. 2015 Jan;4(1):52-7. (PMID: 25787053)
Lancet Neurol. 2021 Aug;20(8):653-670. (PMID: 34139157)
Behav Brain Res. 2001 Nov 1;125(1-2):279-84. (PMID: 11682119)
Neuroimage. 2010 Apr 1;50(2):446-55. (PMID: 20060481)
AJNR Am J Neuroradiol. 2011 Jun-Jul;32(6):1138-42. (PMID: 21527570)
Brain. 2006 Mar;129(Pt 3):584-94. (PMID: 16401620)
J Neurol Neurosurg Psychiatry. 2006 Jan;77(1):51-5. (PMID: 16361592)
Ann Neurol. 2018 Feb;83(2):223-234. (PMID: 29328531)
Neuroimage. 2016 Jul 1;134:281-294. (PMID: 27039700)
Neuroimage. 2012 Jul 16;61(4):1402-18. (PMID: 22430496)
Eur J Neurol. 2021 Dec;28(12):4153-4166. (PMID: 34487400)
Neuroimage Clin. 2019;24:101962. (PMID: 31416017)
Neurol Neuroimmunol Neuroinflamm. 2019 Sep 25;6(6):. (PMID: 32330116)
Nat Commun. 2021 Apr 6;12(1):2078. (PMID: 33824310)
Ann Neurol. 2016 Oct;80(4):499-510. (PMID: 27464262)
Neurology. 1983 Nov;33(11):1444-52. (PMID: 6685237)
Ann Neurol. 2014 Oct;76(4):568-80. (PMID: 25087920)
BMC Med Imaging. 2016 Oct 5;16(1):56. (PMID: 27716096)
Neuroimage. 2002 Sep;17(1):479-89. (PMID: 12482100)
J Neuroimaging. 2020 Jan;30(1):110-118. (PMID: 31571307)
Nat Rev Neurol. 2020 Mar;16(3):171-182. (PMID: 32094485)
Q J Med. 1952 Apr;21(82):135-67. (PMID: 14941968)
J Neurol Neurosurg Psychiatry. 2015 Apr;86(4):410-8. (PMID: 24973341)
J Magn Reson Imaging. 2015 Sep;42(3):698-708. (PMID: 25483607)
J Res Med Sci. 2011 Apr;16(4):457-62. (PMID: 22091259)
PLoS One. 2014 Dec 16;9(12):e115551. (PMID: 25514672)
Lancet. 2002 Dec 21-28;360(9350):2018-25. (PMID: 12504397)
Ann Neurol. 2019 May;85(5):653-666. (PMID: 30851128)
Neurol Sci. 2010 Feb;31(1):29-33. (PMID: 19838623)
Med Image Anal. 2008 Feb;12(1):26-41. (PMID: 17659998)
Springerplus. 2013 May 14;2(1):222. (PMID: 23853744)
Neuroimage. 2011 Jun 1;56(3):907-22. (PMID: 21352927)
Magn Reson Med. 2018 Mar;79(3):1595-1601. (PMID: 28617996)
Neurology. 2018 Jul 24;91(4):e349-e358. (PMID: 29950437)
Lancet Neurol. 2019 Feb;18(2):185-197. (PMID: 30663608)
Front Neurol. 2017 Sep 04;8:433. (PMID: 28928705)
Neuroimage Clin. 2017 Nov 05;17:444-451. (PMID: 29159057)
N Engl J Med. 2010 Feb 4;362(5):387-401. (PMID: 20089952)
J Neurol. 2015 Jul;262(7):1622-8. (PMID: 25929665)
Brain. 2016 Sep;139(Pt 9):2395-405. (PMID: 27401521)
Biom J. 2018 May;60(3):431-449. (PMID: 29292533)
Brain. 2021 Jun 22;144(5):1384-1395. (PMID: 33880511)
Ann Neurol. 2018 Feb;83(2):210-222. (PMID: 29331092)
J Neurol. 2017 Jul;264(7):1402-1412. (PMID: 28600596)
Arch Neurol. 2008 Aug;65(8):1044-51. (PMID: 18541787)
J Neurol Neurosurg Psychiatry. 2008 Nov;79(11):1236-44. (PMID: 18469033)
J Neurol Neurosurg Psychiatry. 2014 Mar;85(3):279-83. (PMID: 23704316)
Brain Pathol. 2018 May;28(3):334-348. (PMID: 28401686)
معلومات مُعتمدة: K23 NS048869 United States NS NINDS NIH HHS; R01 AI131624 United States AI NIAID NIH HHS; R35 NS111644 United States NS NINDS NIH HHS; RO1NS26799 National Institute of Neurological Diseases and Stroke; R01 NS026799 United States NS NINDS NIH HHS; R35NS111644 National Institute of Neurological Diseases and Stroke
تواريخ الأحداث: Date Created: 20211208 Date Completed: 20220210 Latest Revision: 20221017
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC8916838
DOI: 10.1002/ana.26281
PMID: 34878197
قاعدة البيانات: MEDLINE
الوصف
تدمد:1531-8249
DOI:10.1002/ana.26281